Change over period: —
NSE · VIMTALABS
VIMTA LABS
-29.5% from the 52-week high · +22.6% above the low
Vimta Labs Ltd. engages in the provision of contract research and testing. The company is headquartered in Hyderabad, Telangana and currently employs 1,368 full-time employees. The firm is engaged in providing a range of services to biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device, power, cement, oil and gas, ores and minerals, infrastructure and many other industries, government organizations as well as other industry participants. Its services include Drug discovery, development, and drug life cycle management support services; Preclinical research and testing services for medical device companies; Contract research and testing for agrochemical and specialty chemical companies; and Food testing and analytical development services to support manufacturers, processors, farmers, and retailers; Clinical diagnostics services to patients, clinicians, and hospitals, and environmental regulatory services such as impact assessments and post project monitoring, to various industries, such as power and infrastructure.
The short version. VIMTA LABS reported revenue of ₹90 crore for Dec 2024, up 9.8% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Promoter holding was 35.64% in Sep 2026, down 1.12 points over 8 quarters.
1 · The price
How has the stock traded?
VIMTA LABS trades 29.5% below its 52-week high and 22.6% above its 52-week low.
2 · The business
Is it growing?
Dec 2024 revenue of ₹90 cr.
Dec 2024 net profit of ₹21 cr.
11.5 pts higher than a year earlier.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 90 | 85 | 82 | 80 | 82 | 73 | 83 | 82 |
| Net profit | 21 | 15 | 12 | 12 | 10 | 6 | 12 | 13 |
| Net margin % | 23.9 | 18.0 | 15.0 | 15.5 | 12.4 | 8.6 | 14.6 | 15.5 |
| EPS (₹) | 4.84 | 3.44 | 2.77 | 2.79 | 2.29 | 1.43 | 2.75 | 2.87 |
Annual
| FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|
| Revenue | 318 | 318 | 278 | 211 | 181 | 213 |
| Net profit | 41 | 48 | 41 | 21 | 7 | 25 |
| Net margin % | 12.9 | 15.1 | 14.9 | 10.2 | 3.8 | 11.9 |
| EPS (₹) | 9.25 | 10.88 | 9.35 | 4.84 | 1.55 | 5.72 |
3 · The quality
How well does it turn capital into profit?
.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | — | — | 12.8 | 17.1 |
| Return on capital % | — | — | 16.4 | 22.2 |
| EBITDA margin % | — | — | 28.2 | 30.6 |
| Net margin % | — | — | 12.7 | 15.0 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | — | — |
| Profit CAGR | — | — |
4 · The owners
Who holds it, and are they adding?
Down 1.12 pts over 8 quarters.
Up 1.26 pts over 8 quarters.
Down 0.68 pts over 8 quarters.
+1 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 36.76 | 36.7 | 36.67 | 35.99 | 35.9 | 35.85 | 35.67 | 35.64 | -1.12 |
| FII | 3.81 | 3.66 | 3.49 | 4.33 | 4.59 | 4.89 | 4.42 | 5.07 | +1.26 |
| DII | 1.16 | 1.43 | 1.42 | 0.87 | 0.11 | 0.14 | 0.37 | 0.48 | -0.68 |
| Public | 58.27 | 58.2 | 58.42 | 58.8 | 59.41 | 59.12 | 59.55 | 58.8 | +0.53 |
Mutual fund holdings · Oct 2026
3 schemes hold this stock
2 the month before.
- WhiteOak Capital Pharma and Healthcare Fund0.52% of NAV
- Motilal Oswal BSE Healthcare ETF0.05% of NAV
- Bandhan BSE Healthcare Index Fund0.05% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for VIMTA LABS are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Healthcare Services stocks
Quick answers
Common questions about VIMTA LABS
What is the VIMTA LABS share price?
VIMTA LABS (VIMTALABS) last closed at ₹471.95, up 1.1% on the day. Its 52-week range is ₹380.70 to ₹661.75.
What is the market cap of VIMTA LABS?
VIMTA LABS has a market capitalisation of about ₹2,084 crore. Its price-to-earnings ratio is 26.2.
How are VIMTA LABS's latest results?
VIMTA LABS reported revenue of ₹90 crore for Dec 2024, up 9.8% from a year earlier. Net profit was ₹21 crore (up 110.0% year on year). Promoter holding was 35.64% in Sep 2026, down 1.12 points over 8 quarters.
Who owns VIMTA LABS?
As of Sep 2026, shareholding was: Promoter 35.64%, FII 5.07%, DII 0.48%, Public 58.8%.
How many mutual funds hold VIMTA LABS?
3 mutual fund schemes held VIMTA LABS in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 18 Jun 2026 · Final Dividend - Rs. 2
- 13 Jun 2025 · Bonus issue 1:1
- 30 May 2025 · Dividend - Rs. 2
- 11 Jul 2024 · Final Dividend - Rs. 2
- 21 Jun 2023 · Final Dividend - Rs. 2
- 16 Jun 2022 · Dividend - Rs. 2
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.